Hospital readmission risk in pediatric patients was higher in those who were first admitted for RSV than in those who were first admitted for influenza or hMPV.

"We are pleased to announce the Phase I clinical trial initiation of our potential first-in-class combination vaccine candidates SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3), further ...

The ongoing Phase I trial for Clover's combination vaccine candidates is enrolling up to 192 older adults (60-85 years), and the participants will be randomized to receive either SCB-1022 (RSV+hMPV), ...

Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health ...

With the 2025 influenza season starting earlier than usual, the NICD urges South Africans to stay vigilant against seasonal ...

The rapid identification of respiratory virus outbreaks is needed to enable rational and effective public health interventions. We developed new quantitative approaches for simultaneous ...

"We are pleased to announce the Phase I clinical trial initiation of our potential first-in-class combination vaccine candidates SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3), further demonstrating ...

Vermont has the second lowest state fatality rate in the US (148.2 per 100K; Hawaii 113.6/100K). Mississippi (465.8/100K) and ...